and the common consequences were fractures and head injuries. The common bones fractured were the radius and ulna.

**PIH2**

**E-PRESCRIBING REDUCES BEERS PRESCRIBING AMONG THE ELDERLY**

Hutchins DS1, Lewis M2, Valezquez R3, Berger JE1

1 Caremark, Scottsdale, AZ, USA; 2 Caremark, Hunt Valley, MD, USA; 3 OSF Health Plans, Peoria, IL, USA; 4 Caremark, Northbrook, IL, USA

**OBJECTIVES:** The objective of this study was to assess the impact of a PDA-e-prescribing tool (e-tool) on prescribing potentially inappropriate drugs from the Beers List to the elderly. The Beers List documents potentially inappropriate medications that should be avoided or used with caution in patients over the age of 65 years. **METHODS:** All prescription claims (N = 383,855) from April 2002 through June 2003 were extracted for 14,357 plan participants aged 65 and older in which 70 of 3706 prescribers received an e-tool. For each claim, we identified whether the prescription was new and a Beers listed drug and whether the prescriber was an e-tool user and a staff model physician. E-tool use was split into before and after initiation. New prescriptions were classified into 6 and 12-month variables using prior eligibility. Rates were determined as Beers claims counts divided by total claims. We ran chi-square tests and logistic regressions incorporating these and selected demographic variables.

**RESULTS:** After initiating e-tool use, providers prescribed significantly fewer Beers drugs than before across all (7.87% vs. 9.13%, p < 0.0001) and new (6-month: 3.39% vs. 4.68%, p < 0.0056; 12-month: 3.05% vs. 4.78%, p < 0.0025) prescriptions; their before rates did not differ significantly from non-e-tool providers (overall: 9.09% vs. 9.13%, p = 0.8702; 6-month: 5.04% vs. 4.66%, p = 0.5459; 12-month: 3.05% vs. 4.78%, p < 0.9317). Staff providers prescribed significantly fewer Beers drugs overall than non-staff providers (8.88% vs. 9.27%, p = 0.0002), but not for 6-month (5.08% vs. 4.49%, p = 0.0538) or 12-month (4.97% vs. 4.69%, p = 0.5816) new prescriptions. Regressions, accounting for provider degree and specialty, participant sex and age group, and geography, yielded similar results. **CONCLUSION:** E-Tools providing Beers criteria can significantly reduce the prescribing of these drugs among the elderly. Such reductions have been shown to reduce morbidity, mortality, and health care costs.

**INDIVIDUAL’S HEALTH—Cost Studies**

**PIH3**

**COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL CONTRACEPTIVE METHODS**

Gajria KL1, Wallenstein GV1, Hagan MA2

1 QualityMetric Inc, Lincoln, RI, USA; 2 Berlex Laboratories, Inc, Wayne, NJ, USA

**OBJECTIVES:** The objective of this study was to identify the most cost-effective oral or transdermal contraceptives (CCs) using a provider perspective. **METHODS:** A decision analytic model was developed to compare the cost-effectiveness of oral CCs, 3 mg drospirenone/0.02 mg Ethinylestradiol (DRSP-EE), 0.18 mg norgestimate/0.025 mg ethinylestradiol (NO-EE), and 1 mg norethindrone acetate/20 mcg ethinyl estradiol (NA-EE); transdermal CC 6 mg norelgestromin/0.075 mg ethinylestradiol (transdermal N-EE); and no contraceptive use in preventing a pregnancy per patient per year. Direct medical costs were based on average wholesale prices for drugs (Wolters-Kluwer, 2006), and, physician, laboratory and hospital costs based on 2006 Medicare reimbursement rates. Probability data that included compliance and pregnancy rates were extracted from randomized clinical trials and public resources such as the 2002 National Survey of Family Growth. A probabilistic sensitivity analysis of all free parameters was conducted through a Monte Carlo simulation. Key parameters were sampled from beta distributions. **RESULTS:** In the base case, DRSP-EE was found to be the most cost-effective strategy. DRSP-EE cost $688 compared to $766 for NA-EE, $736 for transdermal N-EE, and $729 for NO-EE to prevent a single pregnancy per patient per year. No contraceptive use was the least cost-effective strategy, resulting in approximately $52,529 to prevent a single pregnancy per patient per year. Monte Carlo sensitivity analysis confirmed these findings. Incremental cost-effectiveness analyses revealed that the use of transdermal N-EE costs an additional $86,285 per patient per year to be as effective as DRSP-EE. **CONCLUSION:** In terms of cost-effectiveness, DRSP-EE dominated all contraceptive strategies. The overarching component driving differences in cost-effectiveness was related to direct medical costs associated with pregnancy. These direct medical costs, in turn, were driven by differential compliance and efficacy rates that favored DRSP-EE.

**PIH4**

**THE DIRECT AND INDIRECT COST BURDEN OF TREATED UTERINE FIBROIDS**

Lee DW1, Ozminowski RJ2, Smith Carls G3, Wang S4, Gibson TB5, Stewarc EA6

1 GE Health care, Waukesha, WI, USA; 2 Thomson Medstat, Ann Arbor, MI, USA; 3 Thomson Medstat, Brooklyn, NY, USA; 4 Thomson-Medstat, Cambridge, MA, USA; 5 Brigham and Womens Hospital, Boston, MA, USA

**OBJECTIVES:** Estimate annual direct (medical expenditure) and indirect (absenteeism and short-term disability) costs for women with uterine fibroids (UF). **METHODS:** We compared 12-month direct costs among women aged 18–54 with clinically-significant, symptomatic UF (admission, emergency visit, or >2 office visits >30 days apart with a UF diagnosis) to a 1:1 propensity score matched cohort of women without UF, using the MarketScan Commercial Claims and Encounters insurance database data from for 2000–2004. We also compared indirect costs for the sub-sample of women with available data. Exponential conditional regression analysis controlled for confounding factors, and costs were adjusted to 2004 levels. **RESULTS:** Sample sizes for the direct and indirect costs analyses were 38,080 and 18,200, respectively. Mean 12-month direct costs for women in the UF group were $11,720 vs. $3257 for controls (women without diagnosed or treated fibroids). Mean 12-month indirect costs were $11,752 and $8083 for women in the UF group and controls, respectively. Estimated direct costs attributable to UF were therefore $8463 (p < 0.001) and indirect costs were $3669 (p < 0.001). Employers’ share of direct costs ranged from 84.1% to 87.5%. **CONCLUSION:** Direct and indirect costs of uterine fibroids represent a substantial burden to employers. Treatment options aimed at reducing symptoms and resultant absenteeism are needed to improve women’s health and productivity.

**PIH5**

**SURGICAL COST OF PELVIC ORGAN PROLAPSE IN GERMANY, FRANCE AND ENGLAND**

Subramanian D1, Slack M2

1 Ethicon, Livingston, Scotland, UK; 2 Addenbrookes Hospital, University of Cambridge Teaching Hospitals Trust, Cambridge, UK

**OBJECTIVES:** To estimate the direct cost of surgical interventions for Pelvic Organ Prolapse (POP) to the payers in Germany, France and the National Health Service (NHS) in England.
METHODS: We analyzed the 2004 German InEK Hospital statistics data, the 2005 French Programme de Médicalisation des Systèmes d’Informations (PMSI) database and the 2005–06 NHS England Hospital Episode Statistics (HES) database to estimate the number and type of surgical procedures for POP. We included procedures performed for uterovaginal prolapse, such as colporrhaphy, sacrocoplopexy and sacrospinous colpopexy. Additionally, we identified the total number of hysterectomies; extrapolating from previous studies, we assumed 15% of these were performed for a primary indication of POP. We multiplied the observed number of surgical procedures by the respective 2007 Diagnosis-Related Group (DRG) reimbursement rates to estimate the direct annual surgical cost. RESULTS: Annually, 62,581 POP repair procedures were performed in Germany, 32,392 in France and 23,583 in NHS England. In addition, we estimate that 39,329 hysterectomies are performed for a primary indication of POP across the three healthcare systems. The direct surgical cost of these surgical procedures was €476M. CONCLUSIONS: The annual direct surgical cost of POP to the 3 big European healthcare systems is nearly €500M, highlighting a significant burden to the European payer. This is under-estimate of the true cost of the illness because it does not include other medical costs, cost of conservative management and societal costs. Extrapolating from epidemiological studies, about 30% of POP procedures are repeat surgeries, implying the direct surgical cost of re-operations is approximately €135M. Considering the high financial burden of POP and its recurrence, it is imperative that new standardized procedures with superior outcome are considered, in order to effectively treat the condition, and by doing so, reduce recurrence.

CONTRACEPTIVE AND NON-CONTRACEPTIVE BENEFITS OF A LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN A VERTICALLY INTEGRATED HMO
Brixner DI1, Horowicz-Mehler N2, Stern L3, Doyle J3, Dolgitser M4.
1University of Utah, Salt Lake City, UT, USA, 2Analytica International, New York, NY, USA, 3Berlex Laboratories, Wayne, NJ, USA
OBJECTIVES: In 2001, excessive uterine bleeding was the cause of 1.4 million physician visits in the US. Beyond offering contraceptive benefits, Levonorgestrel-Releasing Intrauterine System (LNG-IUS) is an effective alternative to traditional management of menstrual bleeding disorders. The objective was to describe a population on LNG-IUS and assess contraceptive and non-contraceptive outcomes. METHODS: Women ≥18 years of age with LNG-IUS and ≥1 year of continuous enrollment pre- and post-insertion were identified via a retrospective cohort design utilizing claims data from a Michigan vertically integrated health care system (Jan. 2000–Dec. 2005). Patterns of LNG-IUS use, number of obstetric- and gynecology-related visits, percent of patients with menorrhagia, dysmenorrhea, dysfunctional uterine bleeding, and abnormal uterine bleeding were compared pre- and post-insertion, along with gynecology-related costs. RESULTS: A total of 152 women (mean age 35 ± 8) met study inclusion criteria. Two nested cohorts were distinguished further based on follow-up length as 2-year pre/post (N = 73) and 3-year pre/post (N = 29) groups. Over 90% had a single insertion and ≥04% a LNG-IUS-related complication (e.g. expulsion, perforation, or infection). No LNG-IUS patient experienced a pregnancy with no obstetric-related visits post-insertion for all groups. Thirteen percent of women experienced menorrhagia in the year preceding insertion, down to 12.5%, 1.2% and 0% in the 1, 2 and 3 years post-insertion. Subsequently, mean number of gynecology-related visits decreased from 4 to 2; 7 to 4 and 9 to 4 from the pre- to the post-insertion period for the 1, 2, and 3-year follow-up groups, respectively. Among non-hysterectomized women, mean gynecology-related costs decreased from $1646 per patient in the 3 years preceding LNG-IUS to $1355 in the 3 years post-insertion. CONCLUSION: LNG-IUS avoided pregnancy in all patients and led to decreased bleeding-related events and gynecology-related costs starting in the second year post-insertion. Benefits should become more apparent with longer follow-up.